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ABSTRACT
Background: Chronic myelomonocytic leukaemia
(CMML) is a haematopoietic malignancy with hetero-
geneous clinical and morphological features. It is classified
in the World Health Organization myeloproliferative-
myelodysplastic overlap category. JAK2V617F mutation can
be found in a large percentage of patients with
myeloproliferative neoplasms.
Aims: To investigate the association between JAK2V617F
mutation and clinical, haematological and bone marrow
histological features in CMML and to verify whether the
mutation is associated with the myeloproliferative type of
the disease.
Methods: 78 consecutive patients with newly diagnosed
CMML from 2004 to 2008 were included in the study.
JAK2V617F mutation was assessed using direct sequencing
of exon 14 or by allele-specific PCR from total peripheral
blood or bone marrow samples.
Results: JAK2V617F mutation was identified in eight cases
(10.2%). All patients with the mutation presented with
splenomegaly and had a significantly higher haemoglobin
level and neutrophil count than patients without the
mutation. All bone marrow biopsies of JAK2V617F-mutated
CMML showed increased erythropoiesis, a marked
myeloid and megakaryocytic hyperplasia with occasionally
clustered megakaryocytes, and a mild or moderate (grade
1 or 2) fibrosis; six cases showed an increased number of
dilated sinusoids and reactive lymphoid nodules.
Conclusions: The results indicate that JAK2V617F muta-
tion is associated with clinical and morphological features
of the myeloproliferative type of CMML. Therefore, JAK2
mutation analysis together with bone marrow morphology
could help in a more appropriate classification of the
disease.
Chronic myelomonocytic leukaemia (CMML) is a
clonal disorder of a bone marrow stem cell,
characterised by a persistent peripheral blood
monocytosis. The clinical, haematological and
morphological features of the disease are hetero-
geneous and vary from predominantly myelodys-
plastic to mainly myeloproliferative patterns.1–3
According to the World Health Organization
(WHO) classification of myeloid neoplasias,
CMML is placed in the myeloproliferative-myelo-
dysplastic overlap category.4 However, a more
appropriate classification of the disease would be
desirable.
A somatic point mutation (V617F) in a highly
conserved residue of the pseudokinase domain of
the Janus kinase 2 (JAK2) has been detected in a
large percentage of patients with myeloproliferative
disorders, such as polycythaemia vera (65–97%),
essential thrombocythaemia (23–79%) and primary
myelofibrosis (35–78%).5–9 JAK2V617F mutation has
been rarely observed in patients with myelodysplas-
tic/myeloproliferative diseases or myelodysplastic
syndromes.10–12
The aim of this study was to search for JAK2V617F
mutation in CMML and investigate the relation-
ship with clinical, haematological and bone mar-
row (BM) histological features, to verify whether
the JAK2V617F mutation is associated with the
myeloproliferative type of CMML.
METHODS
Patients
A total of 78 consecutive patients with newly
diagnosed CMML, admitted to the Division of
Haematology, San Giovanni Hospital and
University of Turin, Italy, from 2004 to 2008 were
included in the study. Diagnosis of CMML was
performed according to WHO criteria.4 There were
24 women and 54 men; the mean age was 70 years
(range 36–88 years). The study was carried out
with the approval of the local ethics committee.
BM biopsies were taken during initial investiga-
tion, from posterior–superior iliac crest, using a
Jamshidi needle.
Histology
Specimens were immediately fixed in buffered acid
formol for 24 h, decalcified in Osteodec (EDTA,
HCl mixture; Bioptica, Milan, Italy) for 6 h,
dehydrated, and embedded in paraffin. Serial
sections (3 mm thick) were stained with H&E,
Dominici, Perls and Gomori stains.
Immunohistochemistry was performed with an
automatic stainer device (Dakoautostainer; Dako,
Glostrup, Denmark), using the Labelled
Streptavidin-Biotin 2 System detection kit
(Dako), diaminobenzidine as a chromogen, and
the monoclonal antibodies anti-CD34 (Clone
QBEnd/10), anti-CD31 (clone JC70A), anti-von
Willebrand Factor (Clone F8/86), anti-glycophorin
A (Clone JC159), anti-CD68 (clone PG-M1), and
the polyclonal antibody anti-human myeloperox-
idase (all from Dako, Glostrup, Denmark). The
following histological parameters were evaluated:
marrow cellularity, hyperplasia and dysplasia of
the erythroid, myeloid and megakaryocyte
lineages, percentage of monocytes and CD34-
positive blasts, marrow fibrosis, presence of dilated
sinusoids and reactive lymphoid nodules. Bone
marrow cellularity was determined taking into
account the age-related changes in the study
population.13 The different cell lineages were
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semiquantitatively evaluated by a score that was mainly based
on their frequency in the normal BM:14 0, no increase in
comparison with the normal state; +1, mild increase (corre-
sponding to a mild hyperplasia); +2, moderate increase
(moderate hyperplasia); +3, marked increase (marked hyperpla-
sia). BM fibrosis was graded according to the criteria of the
European consensus on grading bone marrow fibrosis13 and a
semiquantitative scale was used: 0, scattered linear reticulin
with no intersections, corresponding to normal bone marrow; 1,
loose network of reticulin with many intersections, especially in
perivascular areas (corresponding to a mild fibrosis); 2, diffuse
and dense increase in reticulin with extensive intersections,
occasionally with only focal bundles of collagen (corresponding
to a moderate fibrosis). All biopsy specimens were indepen-
dently examined by two pathologists (AP, LG) who had no
knowledge of the mutational status. Disagreement between the
observers was found in less than 10% of the cases. In these cases,
a consensus interpretation was reached after re-examination of
the slides with a double-headed microscope.
JAK2V617F mutation analysis
JAK2V617F mutation testing was performed on peripheral blood
or bone marrow samples. RNA and/or DNA were automatically
extracted by using Maxwell 16 blood DNA purification kit,
Wizard SV 96 genomic DNA purification system or SV96 total
RNA isolation system following the manufacturer’s instructions
(Promega Corporation, Madison, Wisconsin, USA). cDNA was
prepared by reverse transcription following the standardised
BIOMED-1 protocol.15 JAK2V617F mutation was assessed in all
cases using direct sequencing of exon 14 cRNA: PCR primers
(forward: 59-GTAGGAGACTACGGTCAACTG-39; reverse: 59-
TGCATGGCCCATGCCAACT-39) were designed to amplify a
273 bp segment of JAK2 encompassing the codon for amino acid
617. The sequencing reaction was carried out using the Big Dye
Terminator Cycle Sequencing Ready Reaction Kit (Applied
Biosystems, Foster City, California, USA), and the analysis was
performed on an ABI 310 automated capillary system, following
the manufacturer’s instructions. All sequences of samples were
compared with published germ-line sequences using basic local
alignment search tool (BLAST) on the Internet.
In selected cases, allele-specific PCR was also utilised to screen
for the JAK2V617F point mutation on DNA by amplifying JAK2
exon 14.5
Statistical analysis
The independence between categorical variables and JAK2V617F
status was estimated by the Fisher’s exact test. Continuous
variables were compared by the Mann–Whitney U test. All data
were processed with BMDP selected programs (2D, 3D, 7D,
4F).16
RESULTS
JAK2V617F mutation was identified in 8 of 78 cases (10.2%). The
results of the association between JAK2V617F mutation and
clinical, haematological and BM histological features in patients
with CMML are summarised in tables 1 and 2. Of 37 patients
that had palpable splenomegaly, 22 underwent an ultrasound or
CT scan that showed a maximum diameter of the spleen
ranging from 14 to 25 cm. All patients with JAK2V617F mutation
presented with splenomegaly (palpable spleen or echographi-
cally/CT enlarged spleen more than 14 cm in the maximum
diameter), while splenomegaly was found in only 29 of 70
JAK2V617F-negative patients (p = 0.001). Patients with JAK2V617F
mutation had also significantly higher red blood cell count
(4.74761012/l versus 3.59361012/l, p = 0.01), haemoglobin level
(13.1 g/dl versus 10.8 g/dl, p = 0.02) and neutrophil count
(22.6246109/l versus 8.2676109/l, p = 0.02) than patients with-
out the mutation. No association was found for patient age, sex,
white blood cell count, or platelet, monocyte or lymphocyte
count. BM biopsies of CMML with JAK2V617F mutation showed
a mean cellularity of 85% (range 70–100), a mean percentage of
CD34-positive blasts of 5.75% (range 1–15) and a mean
percentage of monocytes of 18.1% (range 15–25); these values
were not different to BM biopsies of non-mutated cases.
Erythroid hyperplasia was found in all mutated cases, but in
only 20 of 70 (28.6%) non-mutated cases (p = 0.0001). A marked
myeloid (fig 1) and megakaryocytic hyperplasia was seen in all
mutated cases, but in only 60% and 50% of non-mutated cases
(p = 0.02 and 0.006, respectively). Megakaryocytes were occa-
sionally clustered and large, with hyperlobulated nuclei (fig 1,
inset). Mild or moderate fibrosis (grade 1 or 2)13 (fig 2) was seen
in all mutated cases, but in only 13 of 70 (18.6%) non-mutated
cases (p,0.00001). An increased number of dilated sinusoids
and reactive lymphoid nodules was seen in six of mutated cases
(75%), but in only 4 (5.7%) and 15 (21.4%) of non-mutated
cases (p,0.0001 and 0.004, respectively).
DISCUSSION
Our results show that JAK2V617F mutation can be detected in a
small number (8/78) of CMML, in accordance with previous
Table 1 Association between JAK2V617F mutation and clinical and
haematological features in chronic myelomonocytic leukaemia (n = 78)
Variable
JAK2V617F positive
(n = 8)
JAK2V617F negative
(n = 70) p Value
Age, years 68.9 (8.3) 70.2 (10.9) 0.4
Haemoglobin, g/dl 13.1 (2.7) 10.8 (2.2) 0.02
WBC count, 6109/l 28.386 (29.77) 18.039 (19.73) 0.1
Platelets, 6109/l 205.5 (277) 139.1 (141) 0.6
Neutrophils, 6109/l 22.624 (27.33) 8.267 (8.62) 0.02
Lymphocytes,
6109/l
2.435 (1.047) 3.230 (4.910) 0.5
Monocytes, 6109/l 2.890 (2.382) 3.631 (4.653) 0.8
Splenomegaly,
n (%)
8 (100) 29 (41.4) 0.001
Values are means (SD), unless otherwise indicated.
WBC, white blood cell.
Table 2 Association between JAK2V617F mutation and bone marrow
histology in chronic myelomonocytic leukaemia (n = 78)
Variable
JAK2V617F
positive (n = 8)
JAK2V617F negative
(n = 70) p Value
Cellularity* 85 (10.7) 83.3 (10.6) 0.8
CD34+ blasts* 5.75 (5.2) 3.04 (3.46) 0.09
Monocytes* 18.1 (3.72) 19.5 (8.2) 0.9
Fibrosis, n (%) 8 (100) 13 (18.6) ,0.00001
Erythroid hyperplasia,
n (%)
8 (100) 20 (28.6) 0.0001
Myeloid hyperplasia,
n (%)
8 (100) 42 (60) 0.02
Megakaryocytic
hyperplasia, n (%)
8 (100) 35 (50) 0.006
Dilated sinusoids, n (%) 6 (75) 4 (5.7) ,0.0001
Reactive lymphoid
nodules, n (%)
6 (75) 15 (21.4) 0.004
Values are mean (SD) percentages, unless otherwise indicated.
Fibrosis, mild or moderate fibrosis (grade 1 or 2).13
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studies reporting mutations in 3%,12 7.8%10 and 13% of
CMML.11 Interestingly, JAK2V617F mutation was associated with
clinical, haematological and BM morphological features sugges-
tive of a myeloproliferative disease. Indeed, the patients with
JAK2V617F mutation all presented with splenomegaly and had
significantly higher haemoglobin level, red blood cell and
neutrophil count than patients without the mutation.
Furthermore, BM biopsy of CMML with JAK2V617F mutation
showed in all cases marked erythroid, myeloid and megakar-
yocitic hyperplasia, with occasionally large and clustered
megakaryocytes. In particular, a mild or moderate fibrosis
(grade 1 or 2)13 was evident in BM biopsy of all mutated CMML,
but in only 13 of 70 non-mutated cases (p,0.00001); an
increased number of dilated sinusoids and reactive lymphoid
nodules was seen in six of the mutated cases, but in only 4 and
15 of 70 non-mutated cases (p,0.0001 and 0.004, respectively).
These findings are in contrast with those of Steensma et al12
who found primarily proliferative features in only one of three
patients with JAK2V617F-mutated CMML, and are also partly
different from those of Jelinek et al11 who reported splenomegaly
and megakaryocytic hyperplasia in only three and five of seven
CMML patients, respectively. An appropriate classification of
CMML is still controversial, and the use of the peripheral white
blood cells at diagnosis ((136109/l) as the single criterion for
subclassificaton of the disease does not seem fully justified.17
Our results indicate that JAK2V617F mutation is associated with
clinical and morphological features of the myeloproliferative
type of CMML. Therefore, JAK2V617F mutation analysis together
with bone marrow histopathology could help to provide a more
appropriate classification of the disease.
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Take-home messages
c Chronic myelomonocytic leukaemia (CMML) is a
haematopoietic malignancy with heterogeneous clinical and
morphological features and is classified in the World Health
Organization myeloproliferative-myelodysplastic overlap
category. JAK2V617F mutation can be found in a large
percentage of myeloproliferative neoplasms.
c All patients with CMML and JAK2V617F mutation displayed
splenomegaly with higher haemoglobin level and neutrophil
count than patients without the mutation. Bone marrow
biopsies of JAK2V617F-mutated CMML showed in all cases an
increased erythropoiesis, a marked myeloid and
megakaryocytic hyperplasia and a mild or moderate fibrosis.
c JAK2V617F mutation is associated with clinical and
morphological features of the myeloproliferative type of
CMML. Therefore, JAK2V617F mutation analysis together with
bone marrow histopathology could help to provide a more
appropriate classification of the disease.
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